Fintel reports that on November 4, 2025, Citizens maintained coverage of Vertex (NasdaqGM:VERX) with a Market Outperform ...

Fintel reports that on November 4, 2025, Stifel maintained coverage of Vertex (NasdaqGM:VERX) with a Hold recommendation.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

That morning, Vertex revealed that its total revenue was slightly over $192 million in the third quarter, a figure that was ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...